---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-23-000502"
form_type: "8-K"
ticker: "CFOR"
cik: "0001293818"
company_name: "CapForce Inc."
filed_at: "2023-04-19T23:59:59+00:00"
generated_at: "2026-06-16T23:25:31.517547+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# OpGen signs non-exclusive distribution deal with Fisher Healthcare for Unyvero platform in U.S.

## Summary
- Fisher Healthcare becomes non-exclusive national distributor for Unyvero A50 platform alongside OpGen's direct U.S. sales.
- Initial focus on FDA-cleared Unyvero LRT (BAL) cartridge for hospitalized pneumonia patients and RUO Unyvero UTI for UTIs.
- Unyvero LRT is first FDA-cleared IVD for bacterial pneumonia and antimicrobial resistance markers.
- Unyvero UTI pivotal trial completed; De Novo classification request submitted to FDA.
- Deal aims to expand Unyvero commercial presence and drive revenue growth in the U.S.

## SEC filing metadata
- accession: 0001079973-23-000502
- form_type: 8-K
- ticker: CFOR
- cik: 0001293818
- company_name: CapForce Inc.
- filed_at: 2023-04-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1293818/000107997323000502/0001079973-23-000502-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1293818/000107997323000502/opgen_8k-041923.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-23-000502
- JSON: https://secwatch.observer/filing/0001079973-23-000502.json
- Plain text: https://secwatch.observer/filing/0001079973-23-000502.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.